CHECKLIST: Pre-review
|
|
- Spencer Mitchell
- 5 years ago
- Views:
Transcription
1 of 5 The purpose of this checklist is to provide support for IRB staff conducting pre-review. This checklist is to be completed by the IRB staff, signed, dated, and retained with the IRB protocol record. IRB Number: Protocol Name: Investigator: Reviewer: Check appropriate box for Submission Type. New Study Amendment Status Change Continuing Review Reportable Event Other (Specify): Regulatory Oversight (Check all that apply) DHHS DOD DOJ EPA FDA DOE ED HUD Items Submitted This submission includes the following: Check the appropriate boxes. Application Sponsor Consent Form Template Scientific Review Documentation Study Protocol Sponsor Assent Form Template Web Sites PH Consent Form(s) Investigators Brochure Questionnaires / Surveys Number of Consent Forms Instructions for Use Patient Diary / Patient Tools or Recruitment Materials IND / IDE / HDE FDA Approval PH Assent Form(s) Advertisement Materials Research Authorization Number of Assent Forms Subject Payment / Retention Materials Interview Materials or Impacted Services Agreements Data Collection / Assessment Forms Other (Specify): Special Determinations (Check all that apply) Children Not significant risk device (FDA) Waiver/alteration of the consent process Children who are wards Non-viable neonates Waiver of consent documentation Pregnant women Neonates of uncertain viability Waiver of consent for emergency research Prisoners Cognitively impaired adults HIPAA Waiver / alteration Missing Materials Study Closure All Amendments, Continuing Reviews, Reportable Events, and Status Changes are Complete. The Study can be closed. Final Contingencies
2 of 5 1 ALL REVIEWS (Check when completed.) Determine whether the activity is Human Subject Research or a HUD. Refer to the CHECKLIST: Human Subject Research Determination. Refer to Non-Committee Review for a Human Subject Research determination if you are uncertain or the activity appears to not be Human Subject Research or a HUD. Determine the laws that apply to the Human Subject Research and indicate these in the Regulatory Oversight section. Determine review type. Refer to the CHECKLIST: Exempt Determination, CHECKLIST: Expedited Review or CHECKLIST: Criteria for Approval and Additional Considerations for HUD. The application is completed accurately. 2 INITIAL REVIEW AND AMENDMENTS (Check the box if the answer is Yes or N/A. Do not check the box if the answer is No.) The research involves the use of a drug and meets the criteria in section 7. ( N/A if no drugs.) The research involves the use of a device and meets the criteria in section 8. ( N/A if no devices.) The research involves the use of advertisement and meets the criteria in section 9. ( N/A if no advertisement.) The research involves payment to subjects and meets the criteria in section 10. ( N/A if no payment.) Any special determinations that need to be made are noted in the Special Determinations section. ( N/A if no Special Determinations.) All materials necessary for review are included, i.e.: Completed Submission Documentation Consent / Assent Document(s) or Script(s) Materials Provided to Subjects Protocol and Appendices Data Collection Instruments(s) CITI current for all study staff Qualifications of key research personnel Sample consent / assent document(s) Product information for device Grant application Investigator brochure for investigational drug Department of Energy Checklist Complete sponsor protocol Package insert for marketed drug Department of Education compliance letter Scientific Review Conflict of Interest declaration Impacted Services Agreement(s) The application is complete and questions are accurately answered, i.e.: IRB review history Number of local subjects Subject withdrawal Objectives Total number of subjects study wide Risks to subjects Background Study timeline Potential benefits to subjects Settings Study endpoint(s) Economic burden to subjects Resources available Procedures involved Consent / assent process * Prior approvals Data or specimen banking Consent / assent documentation* Study design Data management Vulnerable populations* Recruitment methods Privacy Drugs or devices Inclusion / exclusion criteria Confidentiality Multi-site research Injury compensation Data safety monitoring plan Sharing results * Refer to CHECKLIST: Full Board Review The Informed Consent document is formatted as required. (Check the box if the answer is Yes or N/A. Do not check the box if the answer is No.) The header includes: 1) Palmetto Health; 2) the complete study title; 3) sponsors name; 4) Informed Consent for Participation in Research; 5) the IRB # The footer includes: 1) Initials line; 2) Page # The signature section includes: 1) Subject; 2) Person Obtaining Consent; 3) Witness; 4) Minor Assent The consent is written in lay language. The consent is written in a question and answer format. The spelling and grammar are correct. The HIPAA waiver / alteration section and questions are complete and accurately answered. ( N/A if no HIPAA waiver/ alteration.) ( N/A if Initial Review.) 3 CONTINUING REVIEW (Check the box if the answer is Yes or N/A. Do not check the box if the answer is No.) CITI training current for listed study personnel. 4 AMENDMENT (Check the box if the answer is Yes or N/A. Do not check the box if the answer is No.) 5 REPORTABLE EVENT (Check the box if the answer is Yes or N/A. Do not check the box if the answer is No. If one is No information is not complete.)
3 of 5 Date discovered by PI or Research Staff is provided. [PGR requires report within 5 days] Protocol Deviations (Check if Yes. All must be Yes If one is No information is not complete.) Number of similar protocol deviations previously submitted is provided. The measures previously taken to prevent reoccurrence are provided. 6 STATUS CHANGE (Check the box if the answer is Yes or N/A. Do not check the box if the answer is No.) Confirm that the research meets the criteria for closure and note in the Study Closure Section. ( N/A if not Study Closure.) 7 DRUGS (Check if Yes. Both must be Yes If one is No information is not complete. Note: This information is usually in the protocol or the investigators brochure.) IND Requirements (Check if Yes. One must be Yes If all are No IND information is not complete.) The drug has a valid IND. (Check if Yes. Both must be Yes If one is No IND information is not complete.) IND Validation (Check if Yes. At least one must be Yes If all are No IND cannot be validated.) Sponsor protocol imprinted with the IND number. Written communication from the sponsor documenting the IND number. Written communication from the FDA documenting the IND number. (Required if the investigator holds the IND.) Drug Control (Check if Yes. Must be Yes If No information regarding drug control is incomplete.) The plan for storage, control, and dispensing of the drug is adequate to ensure that only authorized investigators will use the drug and that they will use the drug only in subjects who have provided consent. The drug is exempt from the IND requirements (Check if Yes. All criteria for one category must be Yes to be met. If none are met, the drug is not exempt from an IND.) Category # 1 (21 CFR 312.2) The drug is lawfully marketed in the United States. The research is not intended to be reported to the FDA as a well-controlled study in support of a new indication for use nor intended to be used to support any other significant change in the labeling for the drug. The research is not intended to support a significant change in the advertising for the product. The research does not involve a route of administration or dosage level or use in a patient population or other factor that significantly increases the risks (or decreases the acceptability of the risks) associated with the use of the drug product. The research is conducted in compliance with the marketing limitations described in 21 CFR (i.e., the investigation is not intended to promote or commercialize the drug product.) Category # 2 (21 CFR 312.2) A clinical investigation involving use of a placebo when the investigation does not otherwise require submission of an IND. Category # 3 (21 CFR ) The active moiety in the drug product is identical to that in an FDA approved drug. (i.e., the drug product does not contain a new chemical entity.) The drug product is not radioactively labeled. The drug product is not cytotoxic. The dose (single or total daily) does not exceed the dose in the labeling of the approved version of the drug product. The sponsor meets the requirements for retention of test article samples in 21 CFR (d) (1). Category # 4 (21 CFR 361.1) The drug has been approved by a FDA-approved Radioactive Drug Research Committee as a radioactive drugs for certain research use under the criteria in 21 CFR 321.1(b) Category # 5 (21 CFR 361.1) The research is intended to obtain basic information regarding the metabolism (including kinetics, distribution, and localization) of a drug labeled with a cold isotope or regarding human physiology, pathophysiology, or biochemistry. The research is not intended for immediate therapeutic, diagnostic, or preventive benefit to the study subject. The dose to be administered is known not to cause any clinically detectable pharmacologic effect in humans based on clinical data from published literature or other valid human studies. The quality of the cold isotope meets relevant quality standards. IND Oversight for investigators who hold the IND (Check if Yes. One of the following must be Yes ) The investigator does NOT hold the IND. The FDA requirements of a sponsor (including Good Manufacturing Practices (GMP) when applicable) have been assumed by a contract research organization. An audit has documented that the investigator is compliant with FDA sponsor requirements (including GMP when applicable). 8 DEVICES (Check if Yes. Both must be Yes If one is No information is not complete. Note: This information is usually in the protocol.) IDE/HDE Requirements (Check if Yes. One must be Yes If all are No IDE/HDE information is not complete.)
4 of 5 The device has an IDE or HDE. (Check if Yes If one is No IDE/HDE information is not complete.) IDE/HDE Validation (Check if Yes. At least one must be Yes If all are No, IDE/HDE cannot be validated.) Sponsor protocol imprinted with the IDE/HDE number. Written communication from the sponsor documenting the IDE/HDE number. Written communication from the FDA documenting the IDE/HDE number. (Required if the investigator holds the IDE/HDE.) Device Control (Check if Yes. Must be Yes If No, information regarding device control is incomplete.) The plan for storage, control, and dispensing of the device is adequate to ensure that only authorized investigators will use the device and that they will use the device only in subjects who have provided consent. The device qualifies for an abbreviated IDE. (Check if Yes If one is No, information regarding abbreviated IDE is not complete.) Abbreviated IDE (Check if Yes. All must be Yes ) (21 CFR 812.2) The device is not a significant risk device. The device is not a banned by the FDA. The sponsor will label the device in accordance with FDA regulations. Informed consent will be obtained and documented in accordance with FDA regulation. The investigator will comply with FDA requirements for monitoring investigations. The investigator will comply with FDA requirements for records and reports. The investigator will not market or promote the device. Device Control (Check if Yes. Must be Yes If No, information regarding device control is not complete.) The plan for storage, control, and dispensing of the device is adequate to ensure that only authorized investigators will use the device and that they will use the device only in subjects who have provided consent. The device is exempt from the IDE requirements. (Check if Yes. All criteria under one category must be Yes for a category to be met. If none of the categories is met, the device is not exempt from an IDE.) Category # 1 (21 CFR 812.2) The device was not regulated as a drug before enactment of the Medical Device Amendments. (Transitional device.) The device is FDA-approved/cleared. The device is being used or investigated in accordance with the indications in the FDA approved/cleared labeling. Category # 2 (21 CFR 812.2) The device is a diagnostic device. The sponsor will label the device in accordance with FDA regulations. The testing is noninvasive. i The testing does not require an invasive sampling procedure that presents significant risk. The testing does not by design or intention introduce energy into a subject The testing is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure. Category # 3 (21 CFR 812.2) The device is undergoing consumer preference testing, testing of a modification, or testing of a combination of two or more devices in commercial distribution, and the testing is not for the purpose of determining safety or effectiveness and does not put subjects at risk. Category # 4 (21 CFR 812.2) The device is a custom device as defined in 21 CFR 812.3(b), unless the device is being used to determine safety or effectiveness for commercial distribution. IDE Oversight for investigators who hold the IDE (Check if Yes. One of the following must be Yes ) The investigator does NOT hold the IDE. The FDA regulatory requirements of a sponsor (including Good Manufacturing Practices (GMP) when applicable) have been assumed by a contract research organization. An audit has been performed which documents that the investigator is compliant with FDA sponsor requirements (including GMP when applicable). 9 ADVERTISEMENT (Check if Yes or N/A. All three must be checked, if one is No the information is incomplete.) The context (Check if Yes or N/A. All must be checked) The application describes the mode of communication For printed advertisements, the final copy is being reviewed For audio/video tape, the tape is the final version The content: (Check if Yes. All must be checked) Does NOT state or imply a certainty of favorable outcome or other benefits beyond what is outlined in the consent document and the
5 of 5 protocol Does NOT promise free treatment, when the intent is only to say subjects will not be charged for taking part in the research Does NOT include exculpatory language Does NOT emphasize the payment or the amount to be paid, by such means as larger or bold type The advertisement is limited to the information prospective subjects need to determine their eligibility and interest, such as: The name and address of the investigator or research facility The condition under study or the purpose of the research In summary form, the criteria that will be used to determine eligibility for the study A brief list of participation benefits, if any The time or other commitment required of the subjects The location of the research and the person or office to contact for further information For FDA-Regulated research: (Check if Yes. All must be checked) Does NOT make claims, either explicitly or implicitly, that the drug, biologic or device is safe or effective for the purposes under investigation Does NOT make claims, either explicitly or implicitly, that the test article is known to be equivalent or superior to any other drug, biologic or device Does NOT use terms, such as new treatment, new medication or new drug without explaining that the test article is investigational. Does NOT include a coupon good for a discount on the purchase price of the product once it has been approved for marketing. 10 PAYMENT TO SUBJECTS (Check if Yes or N/A. Must be checked, or the information is incomplete.) Requirements for Payments (Check if Yes. All must be checked) All payments are described in the application including: (Check if Yes. All must be checked) Amount Method Timing of disbursement Credit for payment accrues as the study progresses. Payment is not contingent upon completing the entire study. The amount of payment and the proposed method and timing of disbursement is neither coercive nor presented undue influence. Any amount paid as a bonus for completion is reasonable and not so large as to unduly induce subjects to stay in the study when they would otherwise have withdrawn. All information concerning payment, including the amount and schedule of payments, is in the informed consent document. Compensation does not include a coupon good for a discount on the purchase price of the product once it has been approved. i Blood sampling that involves venipuncture is considered non-invasive for purposes of this exemption. The use of surplus samples of body fluids or tissues that are left over from samples taken for non-investigational purposes is also considered non-invasive.
RECRUITING OF AND ADVERTISING FOR SUBJECTS
1. POLICY Steering Committee approved 9/19/11 The informed consent process begins when a potential human research subject first learns of a study, which is usually accomplished through recruitment efforts.
More informationPOLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program POLICY FOR RESEARCH INVOLVING DRUGS, BIOLOGICS OR DEVICES 6/1/2011 Research investigating or evaluating drugs, biologics or devices must
More information1 Purpose. 2 Procedure. Title: FDA-Regulated Research. SOP Number: 1301 Effective Date: June 2, Previous Version Dates:
Previous Version Dates: Title: FDA-Regulated Research SOP Number: 1301 Effective Date: June 2, 2017 1 Purpose FDA regulations apply to research that involves a FDA-regulated test article in a clinical
More informationRules of Human Experimentation
Rules of Human Experimentation Elaine Larson CUMC IRB Chair Associate Dean for Research, School of Nursing Professor of Epidemiology, Mailman School of Public Health Oversight for Human Research Office
More informationHuman Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationUS Special Operations Command Human Research Protection Office
S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More information13 FDA-Regulated Research
13 FDA-Regulated Research FDA regulations apply to research that involves a FDA-regulated test article in a clinical investigation involving human subjects as defined by the FDA regulations. For FDA-regulated
More informationMCW Office of Research Standard Operating Procedure
MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DEVICES Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW Faculty and Staff involved
More information11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics
11.0 FDA-Regulated Research The IRB evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationThe Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
More informationTitle: Department: Approved by: Director, Human Research Review and Compliance
Title: Department: Requirements for Investigational New Drug (IND) for Human- Subjects Research Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare
More informationSOCIAL & BEHAVIORAL TEMPLATE WITH INSTRUCTIONS: 2.0 Background / Literature Review / Rationale for the study:
SOCIAL & BEHAVIORAL TEMPLATE WITH INSTRUCTIONS: Use this template to prepare a document for SOCIAL AND BEHAVIORAL research with the information from the following sections. Depending on the nature of what
More informationHuman Research Protection Program Plan
Revised January 19, 2018 Table of Contents Human Research Protection Program Plan HRP-101 1/19/2018 2 of 13 Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
More informationUSE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH
Policy P.11 Written By: B. Laurel Elder Created: June 3, 2013 Edited Replaces 10-9-2009 Version P.11.4 USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH A. Procedure Contents this procedure
More informationHuman Subjects Protection Program Plan
December 1, 2016 HRP-101 12/1/16 2 of 12 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research... 3 Human Research:... 4 Human Subject as Defined
More informationHuman Research Protection Program. Plan
Human Research Protection Program Plan Revised September 6, 2017 HRP-101 9/6/17 2 of 13 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
More information11.0 FDA-Regulated Research
11.0 FDA-Regulated Research The HSC evaluates the safety or efficacy of all drugs and devices used in research. Studies involving unapproved or investigational drugs or devices will be reviewed to ensure
More informationAdvocate Health Care Network. Human Research Protection Program. Plan
Advocate Health Care Network Human Research Protection Program Plan Revised October 19, 2014 Page 1 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Clinical Trial... 3 Engaged in Human Research...
More informationProtocol Submission Form
Protocol Submission Form 1. Administrative Information Name of Submitting Party: Street: Province/State: Postal/Zip Code: Phone: ( ) E-mail Address: Fax: ( ) Other: ( ) Date: 2. General Study Information
More informationResearch Involving FDA Regulated Devices Policy 606 Version: 1.1 POLICY
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of devices under the oversight of the Food and Drug Administration
More informationEIGHT BASIC ELEMENTS OF INFORMED CONSENT
1/6 This guidance addresses: o Eight Basic elements of informed consent o Additional elements of informed consent o Other information required by the IRB EIGHT BASIC ELEMENTS OF INFORMED CONSENT Required
More informationFDA-Regulated Research
Chapter 18: FDA-Regulated Research Chapter Contents 18.1 FDA-Regulated Research 18.2 Investigational Drugs 18.3 Investigational Medical Devices 18.4 Sponsor-Investigators 18.5 Humanitarian Use Devices
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationUniversity of California, Irvine Human Research Protections Standard Operating Policies and Procedures
University of California, Irvine Human Research Protections Standard Operating Policies and Procedures Policy Number: 41 Title: Investigational Drugs, Agents, and Biologics Date of Last of Revision: 07/28/2006;
More informationHuman Research Protection Program. Plan
Human Research Protection Program Plan Dated: September 4, 2014 HRP-101 9/4/2014 2 of 14 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
More informationSUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES
This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL
More informationInvestigator Manual Revised August 19, 2013
Investigator Manual Revised August 19, 2013 Investigator Manual Page 2 of 31 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationSITE SUBMISSION FORM (SINGLE SITE)
*We accept study submissions by email, fax or mail. 1. STUDY INFORMATION A. Sponsor: Protocol.: Study Title: B. Study Type: Drug, Biologic or Dietary Supplement (please complete section C., then proceed
More informationParticipant Materials and Retention Program Guidelines
Quorum Review IRB(Quorum) considers recruiting activities to be the beginning of the informed consent process. Consequently, in accordance with its authority to approve or disapprove all research activities,
More informationSWOG
SWOG http://swog.org Page 1 of 5 pages Original Release Date: May 2007 Departments Affected: All Revision Date: May 2014 POLICY ON ADVERTISING FOR SUBJECT RECRUITMENT AND TRIAL PROMOTION When Federal human
More informationRecruitment and Participant Study Materials Guidelines
Quorum Review IRB(Quorum) considers recruiting activities to be the beginning of the informed consent process. Consequently, in accordance with its authority to approve or disapprove all research activities,
More informationMCW Office of Research Standard Operating Procedure
MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DRUGS AND BIOLOGICS Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW/FH Faculty
More information1 GENERAL INFORMATION FOR ALL IRB MEMBERS FOR CONVENED MEETINGS Information for Other Business items Educational Materials
HRP-301 8/15/2017 1 of 5 The purpose of this worksheet is to provide support for IRB staff who prepare review materials for convened IRB meetings or prepare materials for Non-Committee Review. This worksheet
More informationINVESTIGATIONAL DEVICES & DRUGS. What is an IRB to do?
INVESTIGATIONAL DEVICES & DRUGS What is an IRB to do? What is a medical device? An instrument, apparatus, implement, machine, contrivance, implant, or in vitro diagnostic reagent Recognized in the official
More informationUC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration
UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual Cindy Gates IRB Administration What is the purpose of the INVESTIGATOR MANUAL? The manual is designed
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationInvestigational New Drug Development Steps for CRCs
Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives
More informationAPPLICATION FORM. Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use.
APPLICATION FORM Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use. Form 1 This application form should be completed and submitted
More informationExpedited Review of Human Subject Research
Expedited Review of Human Subject Research Table of Contents Eligibility for Expedited Review Expedited Review IRB Oversight of Expedited Review Research Categories Eligible for Expedited Review Review
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More informationRecruitment of Research Participants
IOWA STATE UNIVERSITY Institutional Review Board Recruitment of Research Participants Recruitment of research participants takes many forms that involve presenting potential participants with information
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationInvestigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
More informationPROTOCOL DRAFTING GUIDE
MUHC Research Ethics Board (Neurosciences & Psychiatry) Comité d éthique de la recherche du MUHC (Neurosciences & psychiatrie) PROTOCOL DRAFTING GUIDE LIST OF ITEMS TO BE INCLUDED IN A PROTOCL FOR RESEARCH
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More informationClinical Trials Management for Molecular Diagnostics. April 2016
Clinical Trials Management for Molecular Diagnostics April 2016 Clinical Operations Responsibilities Accrue samples that have proper informed consent for use Retrospective cohorts Remnant samples Prospective
More informationIRB APPLICATION OF FDA REGULATIONS Click for Animation
IRB APPLICATION OF FDA REGULATIONS Click for Animation Created 12/2016 Belinda Smith & Jennifer Hill, University of Kentucky Office of Research Integrity Acknowledgement Ada Sue Selwitz FDA IRB Review
More informationBioresearch Monitoring Inspections in Vitro Diagnostics Devices
Seite 1 von 7 U.S. Food and Drug Administration Protecting and Promoting Your Health Bioresearch Monitoring Inspections in Vitro Diagnostics Devices TABLE OF CONTENTS Introduction Nature, Scope, & Purpose
More informationINVESTIGATOR HANDBOOK
INVESTIGATOR HANDBOOK INVESTIGATOR HANDBOOK Table of Contents MISSION... 3 FIRST TIME SUBMISSION... 3 EDUCATIONAL REQUIREMENTS... 3 PRINCIPAL INVESTIGATOR NEW STUDY SUBMISSIONS... 4 VULNERABLE POPULATIONS...
More information3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor
POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities
More informationHuman Research Protection Program Policy
Page 1 of 11 EMERGENCY USE OF AN INVESTIGATIONAL DRUG, BIOLOGICAL PRODUCT OR DEVICE IN HUMAN SUBJECTS RESEARCH POLICY This policy does not limit the authority of a physician to provide emergency medical
More informationInstitutional Review Board. HRP Investigator Manual
Institutional Review Board HRP 103 - Investigator Manual Revised October 2015 Investigator Manual Page 2 of 50 Contents What is the purpose of this manual?... 4 What is Human Research?... 4 What is the
More informationAttachment B: A Guideline for Writing a Clinical Protocol for CPRN
Attachment B: A Guideline for Writing a Clinical Protocol for CPRN This document provides guidelines for protocol submission. It is only guidance, and the format in which you choose to present the information
More informationWCG ACADEMY COURSE OVERVIEW
WCG ACADEMY COURSE OVERVIEW Investigator Course Title Documentation of Informed Consent Duration Ethical Principles Underlying Consent Documentation Long Form Short Form Consent Records Special Considerations
More informationELEMENTS OF A DATA MONITORING PLAN
ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and
More informationGuidance on Requirements of the Sponsor and the Investigator as a Sponsor
Guidance on Requirements of the Sponsor and the Investigator as a Sponsor University of Colorado Denver (UCD) secures assurances from the sponsor or the investigator-sponsor* that the manufacture and formulation
More informationThe Revised Common Rule. Ann Johnson, PhD, MPH IRB Director University of Utah
The Revised Common Rule Ann Johnson, PhD, MPH IRB Director University of Utah Objectives Describe the Changes that Affect the UU IRB What does this mean for ERICA? UPDATE: The postponement to January 2019
More informationH-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS
H-20 Page 1 of 5 Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS PURPOSE: To describe the requirements for McLeod Health IRB review of Humanitarian Use Devices (HUD).
More informationAPPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1
APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD Revised January 2010 Page 1 The IRB Proposal Includes: 1. All documents, other than the informed consent form, should be understandable to an informed
More informationDevice research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.
POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: A DF/HCC Investigator who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities that
More informationEthical Principles in Clinical Research
Ethical Principles in Clinical Research Christine Grady NIH Clinical Center Department of Bioethics No conflicts of interest. Views presented are mine and do not necessarily represent positions or policies
More informationREGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts
REGULATORY ISSUES: HOW TO APPLY FOR AN IND Penny Jester and Maaike Everts Outline 2 What is the purpose of an IND? What types of INDs are there? When do you need one? How do you apply for one? How do you
More informationHUMAN SUBJECTS RESEARCH PROTOCOLS
HUMAN SUBJECTS RESEARCH PROTOCOLS Guidelines and Application Instructions Institutional Review Board (IRB), Office of Sponsored Programs and Research (OSPR) Determine the Type of IRB Review that is Required
More informationInstitutional Review Board Compliance Elizabeth City State University
Institutional Review Board Compliance Elizabeth City State University Michelle Moore, MBA Research Compliance Officer/IRB Administrator Office of Sponsored Programs, Contracts & Grants 110 McLendon Hall
More informationExpanded Access. to Investigational Drugs & Biologics. for Treatment Use
SJMHS Research Compliance Office Guidance Document Expanded Access to Investigational Drugs & Biologics for Treatment Use May 2015 1 Expanded Access to Investigational Drugs & Biologics for Treatment Use
More informationTitle: Review of Medical Devices Page: 1 of 5 Written by:
THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,
More informationROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationInvestigator Manual Revised September 5, 2017
Revised September 5, 2017 Table of Contents Investigator Manual HRP-103 9/5/17 2 of 46 Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationRegulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
More informationQuestion Yes No. 1. Is the study interventional (a clinical trial)? Study Type data element is Interventional
Checklist for Evaluating Whether a Clinical Trial or Study is an Applicable Clinical Trial (ACT) Under 42 CFR 11.22(b) for Clinical Trials Initiated on or After January 18, 2017 1 (NOT FOR SUBMISSION 2
More informationHow to put together an IND application
How to put together an IND application Judit Milstein, Chief, Project Management Staff Judit.milstein@fda.hhs.gov Eithu Lwin, Regulatory Health Project Manager Eithu.Lwin@fda.hhs.gov Division of Transplant
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationRadiation - Florida Department of Health Institutional Review Board
500-26 Radiation 500-26 Radiation - Florida Department of Health Institutional Review Board Protocol title: Researcher: Application contact: For questions, concerns, to provide input, or request a consultation,
More informationHUMAN RESEARCH PROTECTION PROGRAM PLAN
HUMAN RESEARCH PROTECTION PROGRAM PLAN HRP 101 June 2017 706-542-3199 irb@uga.edu https://research.uga.edu/hso/ Table of Contents Scope... 2 Purpose... 2 Definitions... 2 Agent... 2 Clinical Trial... 2
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationRequirements for Humanitarian Use Device (HUD)
Requirements for Humanitarian Use Device (HUD) 1. Definition of Humanitarian Use Device - The definition of a HUD is a device that is intended to benefit patients in the treatment and diagnosis of diseases
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationTrends in Oversight of Human Research Protections?
Trends in Oversight of Human Research Protections? Greg Koski, PhD, MD Associate Professor, Harvard Medical School Senior Scientist, James Mongan Institute for Health Policy Former Director, Office for
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationOutline of Discussion
This final rule is intended to better protect human subjects involved in research, while facilitating valuable research and reducing burden, delay, and ambiguity for investigators. These revisions are
More informationInvestigational New Drug Application
Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution
More informationExpanded Access and the Individual Patient IND
Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office
More informationHuman Research Protection Program Policy
Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving
More informationIs Your Research Involving Human Subjects Eligible for Exemption? John M. Falletta, M.D. Professor of Pediatrics Senior Chairman, DUHS IRB
Is Your Research Involving Human Subjects Eligible for Exemption? John M. Falletta, M.D. Professor of Pediatrics Senior Chairman, DUHS IRB Exemption From What??and/or By Whom? Scrutiny by anyone? SBR review?
More informationNorthwestern University HSPP Policy Manual Page 2 of 116
Northwestern University HSPP Policy Manual Page 2 of 116 POLICY FOR HUMAN SUBJECTS RESEARCH AT NORTHWESTERN UNIVERSITY 8 I. PREAMBLE: 8 II. OVERVIEW OF THE IRB, OPRS, AND THE HUMAN SUBJECT PROTECTION PROGRAM
More informationThe Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation
The Role of the IRB in Clinical Trials: What Patients and Families Need to Know Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation 1 CAC2 Values v Put the children and their families first in
More informationPREP Course 24: Defining the Differences between FDA and OHRP regulations. Presented by: Hallie Kassan Dorean Flores Office of the IRB
PREP Course 24: Defining the Differences between FDA and OHRP regulations Presented by: Hallie Kassan Dorean Flores Office of the IRB CME Disclosure Statement The North Shore LIJ Health System adheres
More informationAnnual Research Administrators Symposium IRB Compliance. Thursday, July 31, 2014
Annual Research Administrators Symposium IRB Compliance Thursday, July 31, 2014 Why IRB Compliance Is Required for Grant Submissions Topics to Cover Today What is an IRB? Why IRB review is required? Regulatory
More informationCONTACT INFORMATION. PHRC Office. Josephine O Driscoll-Davis. Michael Ducey
PHRC Office CONTACT INFORMATION 116 Huntington Ave., 10 th Floor Boston, MA 02116 http://healthcare.partners.org/phsirb Josephine O Driscoll-Davis Assistant Director Administrative Chair (617) 424-4107
More informationRegulatory Binder Guidance
Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization
More informationTo document the review procedures for a submission regarding compassionate/treatment use of investigational drugs, biologics and devices.
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD COMPASSIONATE/TREATMENT USE OF MEDICAL DRUGS, BIOLOGICS AND DEVICES I. PURPOSE To document the review procedures for a submission
More informationThe Institutional Review Board (IRB) Manual
The Institutional Review Board (IRB) Manual Investigational Devices Policy Research that involves the use of investigational devices must conform to Food and Drug Administration (FDA) and Department of
More informationTip Sheet 17: Review of Research by the Expedited Procedure
Tip Sheet 17: Review of Research by the Expedited Procedure Related Accreditation Elements: II.2.E. Policies and procedures should describe review using the expedited procedure, when an expedited procedure
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationHuman Subjects Protection: Training for Research Teams
Human Subjects Protection: Training for Research Teams Walter L. Calmbach MD MPH South Texas Ambulatory Research Network (STARNet) Dept. of Family & Community Medicine Univ. of Texas Health Science Center
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More informationRegulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More information1 of 5 11/6/2014 3:08 PM
1 of 5 11/6/2014 3:08 PM : Thursday, November 6, 2014 1:07:42 PM : NU SF: Basic Information 1. * Title of study: Biomedical Research Study 2. * Short title: Biomedical Study 3. * Brief description: This
More information